NCT04381962View on ClinicalTrials.gov

A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)

PHASE3CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

January 29, 2021

Study Completion Date

April 20, 2021

Conditions
COVID-19
Interventions
DRUG

Azithromycin Capsule

Azithromycin 500 mg OD PO 14 days

Trial Locations (5)

OX3 9DU

Horton General Hospital, Banbury

John Radcliffe Hospital, Oxford

DD2 1SG

Ninewells Hospital, Dundee

B18 7QH

Birmingham City Hospital, Birmingham

B71 4HJ

Sandwell General Hospital, West Bromwich

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Oxford

OTHER

NCT04381962 - A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2) | Biotech Hunter | Biotech Hunter